eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Journal's reviewers Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
3/2020
vol. 37
 
Share:
Share:
more
 
 
abstract:
Review paper

The exposure to biologic and targeted synthetic disease-modifying antirheumatic drugs in pregnancy and lactation

Alicja Góralczyk
1
,
Katarzyna Kolossa
1
,
Marzena Waszczak-Jeka
2
,
Rafał Adamczak
3
,
Sławomir Jeka
1, 4

1.
Department of Rheumatology and Connective Tissue Diseases, University Hospital No. 2, Bydgoszcz, Poland
2.
Medycyna Kliniczna, Warsaw, Poland
3.
Department of Obstetrics and Gynaecology, University Hospital No. 2, Bydgoszcz, Poland
4.
Collegium Medicum in Bydgoszcz, University of Nicolaus Copernicus in Torun, Poland
Adv Dermatol Allergol 2020; XXXVII (3): 306-312
Online publish date: 2020/07/14
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Chronic inflammatory diseases often affect women of childbearing age. Since biologic and targeted synthetic disease-modifying antirheumatic drugs (bDMARDs and tsDMARDs) are more available, their use during conception, pregnancy and lactation has become a matter of concern. Current studies prove the safety of innovative therapy in pregnant women and may contribute to its wider use than before in pregnancy and lactation. It mainly concerns tumour necrosis factor a (TNF-a) inhibitors. We searched PubMed using Medical Subject Headings (MeSH) terms and identified relevant studies and guidelines. We present up-to-date knowledge of bDMARDs and tsDMARDs safety in pregnant and breastfeeding women.
keywords:

bDMARDs, tsDMARDs, inflammatory disease, pregnancy, lactation

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe